2025 Generic and Biosimilar Medicines Savings Report Highlights Value and Vulnerability
By John Murphy III, President & CEO, AAM In 2024, generic and biosimilar medicines comprised 90 percent of all prescriptions filled, but only 12 percent of prescription spending. In sharp contrast, brand drugs supported patients less often—making up only 10 percent of prescriptions filled but adding up to 88 percent of the total drug spend. […]
2025 U.S. Generic & Biosimilar Medicines Savings Report
2025 Savings Report 2025 U.S. Generic & Biosimilar Medicines Savings Report AAM’s annual savings report, in partnership with the IQVIA Institute, reveals the use of Food & Drug Administration (FDA) approved generic and biosimilar medicines created $467 billion in savings in 2024 for patients and the U.S. healthcare system—and $3.4 trillion in savings the last […]
AAM Commends Q1/Q2 House Bill Reintroduction
Reps. Dunn and Mullin bill will cut red tape, bring lower-cost medicines to patients faster, and save more than $800 million over ten years WASHINGTON (March 7, 2025) — The Association for Accessible Medicines today applauded the reintroduction of Q1/Q2 legislation in the U.S. House of Representatives by Congressmen Dunn of Florida and Mullin of […]
AAM & Biosimilars Council Statement on Presidential Election
WASHINGTON, DC (November 7, 2024) — The Association for Accessible Medicines and the Biosimilars Council today released the following statement from President and CEO John Murphy III on the 2024 Presidential and Congressional elections. We congratulate President-Elect Donald Trump and the newly elected and re-elected Members of Congress. AAM and the Biosimilars Council as always […]
$2 Generics List Not the Solution
Does not address PBM abuses or ensure generic sustainability WASHINGTON, DC (October 16, 2024) – The Association for Accessible Medicines today commented on the Centers for Medicare & Medicaid Services request for information on a potential demonstration program to test the use of a $2 copay for certain generic drugs for Medicare recipients. AAM reiterated […]
40 Years of Hatch-Waxman – Trillions in Savings for Patients
Future patient access and savings at risk without action WASHINGTON (September 24, 2024) — Today marks the 40th Anniversary of the enactment of Hatch-Waxman, the landmark Drug Price Competition and Patent Restoration Act of 1984. The Association for Accessible Medicines and its Biosimilars Council today marked the anniversary. 40 years ago today, the generic medicines […]
Generic Medicines Increase Patient Access More Than Government Negotiated Price Controls
Congress and regulators encouraged to stop patent abuses and streamline approvals WASHINGTON (September 18, 2024) — The Association for Accessible Medicines and its Biosimilars Council today responded to current discussions over potential savings on GLP-1 class medications. AAM appreciates Chairman Sanders and his interest in generic competition, and AAM members are committed to increasing patient […]
Want to Save Patients Money on Medicine? No Need to Reinvent the Wheel
Generics and Biosimilars Delivered Record Savings in 2023 As the 2024 U.S. Generic & Biosimilar Medicines Savings Report shows—and as we celebrate the 40th anniversary of the Hatch-Waxman Act—it’s more critical than ever for policymakers to protect generic and biosimilar competition. Delays in competition are costing patients, while generic and biosimilar medicines continue to offer […]
2024 U.S. Generic & Biosimilar Medicines Savings Report
2024 Savings Report 2024 U.S. Generic & Biosimilar Medicines Savings Report AAM’s annual savings report, in partnership with the IQVIA Institute, reveals that the use of Food & Drug Administration (FDA) approved generic and biosimilar medicines created $445 billion in savings in 2023 for patients and the U.S. healthcare system—and over $3 trillion in savings […]
Generic and Biosimilar Medicines Save $445 Billion in 2023
Industry that Saved $3.1 Trillion Since 2014 at Great Risk Without Immediate Action WASHINGTON (September 5, 2024) — The Association for Accessible Medicines, the trade association representing generic and biosimilar manufacturers, today released its 2024 U.S. Generic & Biosimilar Medicines Savings Report. AAM’s annual savings report reveals that the use of Food and Drug Administration […]
AAM White Paper: Hatch-Waxman Turns 40
The 1984 law has enabled trillions of dollars in savings; but the industry is at risk TAMPA, FL (February 6, 2024) — The Association for Accessible Medicines, the leading trade association for generic and biosimilar manufacturers, today released a new report touting the lasting benefits the generic drug industry has provided to patients, employers and […]
AAM Requests Federal Injunction to Block Illinois’ Unconstitutional Drug Price Law
Generic Pharmaceutical Trade Group Steps in to Protect Patient Access to Affordable Generic Drugs WASHINGTON D.C. (January 23, 2024) – Today, the Association for Accessible Medicines (AAM), the trade association representing America’s manufacturers of generic and biosimilar medicines, filed a lawsuit against Illinois Attorney General Kwame Raoul, requesting that a Federal district court in Illinois enjoin the […]
